Physiogenex is a company that provides preclinical in vivo and ex vivo contract research services. It focuses on drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia, and atherosclerosis. The company provides classical and proprietary diet-induced in vivo models, innovative in-house techniques (RCT), as well as in vivo preclinical imaging services.